New pancreatic cancer drug stops tumor growth in 90% of patients

Unlock Editor’s Digest for free

A new pancreatic cancer drug has shown mounting evidence that it can extend the survival time of people with the notoriously deadly disease.

The drug stopped the growth of tumors in 90 percent of participants, shrank them by more than 60 percent, and made them undetectable in 8 percent, in a small-scale trial that followed 61 patients for an average of 18 months.

The findings build on encouraging data this year that showed patients taking the drug in a daily pill form had a median survival time of 13.2 months, 6.5 months longer than those on chemotherapy. The drug, known as daraxonrasib, was approved for certain patient groups by U.S. regulators in August and by the European Commission this week.

The latest results provide “a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option,” said Wungki Park, a medical oncologist at Memorial Sloan Kettering Cancer Center, who participated in the trial whose results were presented at a cancer conference in Barcelona on Thursday.

“With longer follow-up and a broader patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control,” Park said.

The drug made by Revolution Medicines in the United States works by suppressing mutated proteins, particularly those of a class known as KRAS, that fuel tumor growth. This raised hopes that the approach could be extended to other types of cancers.

Pancreatic cancer is particularly deadly because it often causes few or no symptoms initially, meaning it has often spread to other parts of the body by the time it is discovered.

Cancer experts have so far praised daraxonrasib’s results, while noting that it is not a cure and requires further research to fully understand its effectiveness.

“This is the biggest progress we have seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult to treat cancers,” said Michelle Mitchell, chief executive of Cancer Research UK. “These results raise the exciting possibility that this advance could eventually pave the way for the treatment of other cancers with KRAS gene mutations.” »

Survival for pancreatic cancer is still very low, she said. More research is needed to determine how to combine daraxonrasib with other therapies “to give patients the best chance of beating the disease,” she added.

The new drug comes as scientists grapple with conflicting cancer trends. While five-year survival rates for many cancers have increased sharply over the past 50 years thanks to prevention, lifestyle improvements and smart medications, the incidence of some cancers has increased in younger people.

Gn Health

Logo